Key Developments For Response Genetics, Inc.
Response Genetics, Inc. (RGDX.O) (Consolidated Issue listed on NASDAQ Capital Market)
Response Genetics, Inc. Announces Nationwide Launch of New Gastric Cancer Diagnostic Test
Response Genetics, Inc. announced the availability of its ResponseDX: Gastric genetic test panel, a PCR-based diagnostic test. By analyzing the expression of genes that correlate with response to commonly used chemotherapy agents, physicians can better tailor treatment for their patients with gastric cancer and gastroesophageal (GE) junction cancer.
Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc.
The Addario Lung Cancer Medical Institute (ALCMI) announced the execution of a letter of intent (LOI) to collaborate with Response Genetics, Inc. on molecular diagnostic testing and banking of advanced-stage Lung Cancer tissues. Specific molecular features of tumors, including EGFR mutations, ras mutations, ERCC1, RRM1 or TS overexpression, have been shown in multiple studies to have prognostic importance and/or be associated with benefit from specific interventions. Only a minority of patients with Lung Cancer, especially advanced stage disease, are having these molecular assessments performed. As a result of ALCMI's efforts to address this inequity, RGI will employ its panel of clinically-validated genetic tests , ResponseDX: Lung, and rapidly communicate the results with the patients' physicians.
Response Genetics, Inc. Announces $4 Million Private Placement
Response Genetics, Inc. announced that it has entered into a purchase agreement with certain funds managed by Lansdowne Partners Limited Partnership to raise approximately $4 million from the private placement of 3,057,907 newly issued shares of its common stock, at a purchase price of $1.30 per share. The closing of the sale of the shares occurred simultaneously with the signing of the purchase agreement on July 22, 2009. The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from the registration requirements.
Response Genetics, Inc. Expands ResponseDX: Lung And ResponseDX: Colon Genetic Tests To Include Additional Patented Biomarkers Associated With Chemotherapy Response
Response Genetics, Inc. announced that it has expanded its ResponseDX: Lung genetic test panel to assess thymidylate synthase (TS), the expression of which is associated with sensitivity to pemetrexed, a drug used to treat non small cell lung cancer (NSCLC). The Company also announced the inclusion of EGF receptor (EGFR) gene expression to its ResponseDX: Colon genetic test panel, providing additional sensitivity to the widely used chemotherapy combination irinotecan, fluorouracil and folinic acid (FOLFIRI). Both ResponseDX panels are available nationwide through the Company's expanded national sales force.
Response Genetics, Inc. Announces $2 Million Private Placement
Response Genetics, Inc. announced that it has entered into a purchase agreement with certain affiliated funds of Special Situations Funds to raise $2 million from the private placement of 2,000,000 newly issued shares of its common stock, at a purchase price of $1.00 per share. The closing of the sale of the shares is expected to occur on Monday, March 2, 2009.
